Development of Novel Mucosal Vaccines: Advances in Technology and Delivery
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".
Deadline for manuscript submissions: 31 January 2026 | Viewed by 2150
Special Issue Editor
Interests: vaccine development; autoimmunity; immunotherapy
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to this Special Issue, where we aim to focus on pathogens that invade the body through mucosal sites. Examples of this include oral and intranasal vaccination, which have emerged as promising approaches for mucosal vaccine delivery. Technological advancements in mucosal vaccination have heightened immunological responses, simplified administration, and enhanced efficacy. The primary objective of this Special Issue is to describe the latest technological developments that enable the effective delivery of vaccines, specifically focusing on mucosal vaccines and their development, production, processing, and design. Additionally, novel vaccine platforms for mucosal immunization, such as mRNA, DNA, viral vectors, live attenuated bacteria, bacterial vectors, and encapsulation techniques, are of interest.
We look forward to receiving your contributions.
Best regards,
Dr. Mohamed I. Husseiny El-Sayed
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oral vaccines
- nasal vaccines
- live attenuated vaccines
- DNA vaccines
- mRNA vaccines
- viral vectors vaccine
- nanoparticle delivery system
- adjuvants
- gene-based vaccine
- microencapsulation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
